Cellbox closes €5M Series A for warm-chain cell logistics push
What's the deal? Cologne-based Cellbox Solutions has completed the final closing of its Series A, bringing total proceeds to €5 million. CompanistoDealroom has a profile for this one. Try Dealroom → led the first tranche, with new backers including members of Baltic Business Angels Invest, a Canadian family office, and an undisclosed investor with pharmaceutical logistics experience. Existing investors NRW.BANK and Fraunhofer VentureDealroom has a profile for this one. Try Dealroom → also took part.
What does Cellbox do? Founded in 2017, the company makes warm-chain logistics technology for transporting living biological materials. Its Cellbox Go and Cellbox Shipper incubators maintain controlled temperature and CO₂ conditions during ground and air transport, and are already used internationally in research and cell therapy.
Why now? The final close follows an initial tranche of roughly €3.5 million in March 2026. With over 400 Cellbox systems on the market and Drug Master Files for its product family, the company says it is ready to broaden its commercial model.
What's the endgame? Cellbox plans to move beyond transport equipment into integrated logistics for cells, tissues, and organoids. That includes pairing its systems with rental and recurring services such as monitoring, fleet management, and shipment coordination, plus expansion in Europe, Asia, and North America.
"With the successful completion of our Series A round, we are now expanding our established warm-chain technology platform into a broader offering for physiological logistics," said founder and chief executive officer Kathrin Adlkofer.
The signal: At €5 million, the round sits in the lower tier of venture financings by size, reflecting a targeted raise in a specialised niche rather than a landmark deal. It arrives as the cell therapy field grapples with a logistics bottleneck — in October, ARPA-H-backed teams received up to $7.3 million each to pursue room-temperature preservation, a technology that could eventually cut reliance on specialised transport. Cellbox's controlled warm-chain approach signals commercial expansion within that niche, not a solution to the broader cold-chain challenge.
Read more: eqs-news.com
Image credit: Generated with Gemini
